FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947280712> ?p ?o ?g. }

• W2947280712 endingPage "5033" @default.
• W2947280712 startingPage "5033" @default.
• W2947280712 abstract "5033 Background: To develop a new treatment modality, we conducted a phase III randomized trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA) -A24 positive patients with castration-resistant prostate cancer (CRPC) who failed docetaxel chemotherapy. Methods: Patients were randomly assigned in a 2:1 ratio to receive PPV or placebo. Four of 12 warehouse peptides selected based on preexisting peptide-specific immunoglobulin G levels or the corresponding placebo were subcutaneously injected 6 doses weekly followed the maximum of 30 doses bi-weekly until disease progression. The primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS) and immune responses. Results: From August 2013 to April 2016, 310 patients were randomly assigned (207 to PPV and 103 to placebo), and 306 patients were analyzed by the full analysis set (204 to PPV and 102 to placebo). Baseline characteristics were balanced between groups. Estimated median OS was 16.1 months (95% CI, 13 to 18.2) with PPV and 16.9 months (95% CI, 13.1 to 20.4) with placebo (HR, 1.04; 95%CI, 0.79 to 1.37; P = 0.77). Median PFS was also not significantly different among them. Median Grade ≥ 3 adverse events were observed in 41% in both groups. The analysis of treatment arm effects among various subgroups revealed a lower HR for OS in favor of the PPV arm in patients with a < 64% neutrophil proportion (HR, 0.55; 95%CI, 0.33 to 0.93), with a significant interaction test ( P = 0.003). Conclusions: PPV did not prolong either OS or PFS in HLA-A24 positive patients with CRPC progressing after docetaxel chemotherapy. Clinical trial information: 0000113088." @default.
• W2947280712 created "2019-06-07" @default.
• W2947280712 creator A5017624165 @default.
• W2947280712 creator A5032570626 @default.
• W2947280712 creator A5034428180 @default.
• W2947280712 creator A5035661629 @default.
• W2947280712 creator A5038227732 @default.
• W2947280712 creator A5039271211 @default.
• W2947280712 creator A5039879291 @default.
• W2947280712 creator A5041265628 @default.
• W2947280712 creator A5041892488 @default.
• W2947280712 creator A5044424550 @default.
• W2947280712 creator A5045476512 @default.
• W2947280712 creator A5051803042 @default.
• W2947280712 creator A5058934672 @default.
• W2947280712 creator A5076120482 @default.
• W2947280712 creator A5082751122 @default.
• W2947280712 creator A5085955274 @default.
• W2947280712 creator A5089760587 @default.
• W2947280712 date "2019-05-20" @default.
• W2947280712 modified "2023-09-27" @default.
• W2947280712 title "Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo-controlled, phase III trial." @default.
• W2947280712 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.5033" @default.
• W2947280712 hasPublicationYear "2019" @default.
• W2947280712 type Work @default.
• W2947280712 sameAs 2947280712 @default.
• W2947280712 citedByCount "2" @default.
• W2947280712 countsByYear W29472807122020 @default.
• W2947280712 crossrefType "journal-article" @default.
• W2947280712 hasAuthorship W2947280712A5017624165 @default.
• W2947280712 hasAuthorship W2947280712A5032570626 @default.
• W2947280712 hasAuthorship W2947280712A5034428180 @default.
• W2947280712 hasAuthorship W2947280712A5035661629 @default.
• W2947280712 hasAuthorship W2947280712A5038227732 @default.
• W2947280712 hasAuthorship W2947280712A5039271211 @default.
• W2947280712 hasAuthorship W2947280712A5039879291 @default.
• W2947280712 hasAuthorship W2947280712A5041265628 @default.
• W2947280712 hasAuthorship W2947280712A5041892488 @default.
• W2947280712 hasAuthorship W2947280712A5044424550 @default.
• W2947280712 hasAuthorship W2947280712A5045476512 @default.
• W2947280712 hasAuthorship W2947280712A5051803042 @default.
• W2947280712 hasAuthorship W2947280712A5058934672 @default.
• W2947280712 hasAuthorship W2947280712A5076120482 @default.
• W2947280712 hasAuthorship W2947280712A5082751122 @default.
• W2947280712 hasAuthorship W2947280712A5085955274 @default.
• W2947280712 hasAuthorship W2947280712A5089760587 @default.
• W2947280712 hasConcept C121608353 @default.
• W2947280712 hasConcept C126322002 @default.
• W2947280712 hasConcept C126894567 @default.
• W2947280712 hasConcept C141071460 @default.
• W2947280712 hasConcept C142724271 @default.
• W2947280712 hasConcept C143998085 @default.
• W2947280712 hasConcept C147483822 @default.
• W2947280712 hasConcept C168563851 @default.
• W2947280712 hasConcept C195616568 @default.
• W2947280712 hasConcept C197934379 @default.
• W2947280712 hasConcept C203014093 @default.
• W2947280712 hasConcept C203092338 @default.
• W2947280712 hasConcept C204787440 @default.
• W2947280712 hasConcept C27081682 @default.
• W2947280712 hasConcept C2776694085 @default.
• W2947280712 hasConcept C2776789287 @default.
• W2947280712 hasConcept C2780192828 @default.
• W2947280712 hasConcept C2781190966 @default.
• W2947280712 hasConcept C71924100 @default.
• W2947280712 hasConcept C90924648 @default.
• W2947280712 hasConceptScore W2947280712C121608353 @default.
• W2947280712 hasConceptScore W2947280712C126322002 @default.
• W2947280712 hasConceptScore W2947280712C126894567 @default.
• W2947280712 hasConceptScore W2947280712C141071460 @default.
• W2947280712 hasConceptScore W2947280712C142724271 @default.
• W2947280712 hasConceptScore W2947280712C143998085 @default.
• W2947280712 hasConceptScore W2947280712C147483822 @default.
• W2947280712 hasConceptScore W2947280712C168563851 @default.
• W2947280712 hasConceptScore W2947280712C195616568 @default.
• W2947280712 hasConceptScore W2947280712C197934379 @default.
• W2947280712 hasConceptScore W2947280712C203014093 @default.
• W2947280712 hasConceptScore W2947280712C203092338 @default.
• W2947280712 hasConceptScore W2947280712C204787440 @default.
• W2947280712 hasConceptScore W2947280712C27081682 @default.
• W2947280712 hasConceptScore W2947280712C2776694085 @default.
• W2947280712 hasConceptScore W2947280712C2776789287 @default.
• W2947280712 hasConceptScore W2947280712C2780192828 @default.
• W2947280712 hasConceptScore W2947280712C2781190966 @default.
• W2947280712 hasConceptScore W2947280712C71924100 @default.
• W2947280712 hasConceptScore W2947280712C90924648 @default.
• W2947280712 hasIssue "15_suppl" @default.
• W2947280712 hasLocation W29472807121 @default.
• W2947280712 hasOpenAccess W2947280712 @default.
• W2947280712 hasPrimaryLocation W29472807121 @default.
• W2947280712 hasRelatedWork W2010765098 @default.
• W2947280712 hasRelatedWork W2060708716 @default.
• W2947280712 hasRelatedWork W2080820783 @default.
• W2947280712 hasRelatedWork W2094570582 @default.
• W2947280712 hasRelatedWork W2135620818 @default.
• W2947280712 hasRelatedWork W2407641156 @default.
• W2947280712 hasRelatedWork W2568045406 @default.
• W2947280712 hasRelatedWork W2588988563 @default.

• next